# DATO-BASE (NCT06176261)

> DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06176261
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Nancy Lin, MD
- Conditions: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer
- Interventions: Datopotamab Deruxtecan
- Enrollment: 58
- Primary outcome: Objective Response Rate (ORR) in RANO-BM Criteria

## Indexed commentary on DATO-BASE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 16 posts on X
- 4 YouTube videos
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=dato-base-nct06176261

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06176261", "email": "<work email>"}; the inbox owner confirms by the emailed link.